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1269–75.ReplyThe Latest Generation of
Troponin Immunoassays
The “Cholesterol” of the
Third Millennium?We agree with Drs. Lippi and Cervellin that troponin levels may be
useful to target treatments that reduce cardiovascular risk. In our
analysis (1), the number of patients treated with pravastatin to pre-
vent 1 coronary heart disease (CHD) death or nonfatal myocardial
infarction was 29 when troponin I was 0.18 mmol/l (the highest
tertile) compared with 39 patients with troponin I between 0.006
and <0.18 ng/ml and 52 patients in the lowest tertile with non-
detectable troponin I levels (<0.006 ng/ml) at baseline. Patients with
elevated troponin I levels were, therefore, more likely to beneﬁt from
pravastatin. However, high-intensity statins are recommended for all
patients with known CHD (2), and similar analyses have not been
performed in primary prevention trials of statins, where estimates of
cardiovascular risk are more relevant to treatment decisions.
Measuring troponins could also improve targeting of other
preventive treatments. In the LIPID (Long-Term Intervention
With Pravastatin in Ischaemic Disease) study, compared with pa-
tients with nondetectable troponin I levels, those with troponin
I 0.18 mmol/l were 2.6 times more likely to experience a stroke,
2.4 times more likely to develop heart failure, and 2.2 times more
likely to die of cardiovascular causes. It is possible that beta-
blockers, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and other treatments that reduce blood pressure
and improve left ventricular function could have greater absolute
beneﬁts in such patients with higher risks. Troponins have been
shown to predict cardiovascular events in general population co-
horts (3), but in this setting, it is not known whether and which
treatments may reduce the risk associated with troponin elevation.We agree that current evidence suggests that, pending a cost-
effectiveness analysis, it may be reasonable to include measure-
ment of high-sensitivity troponin T or I to identify individuals at
higher risk of cardiovascular events and possibly to integrate change
in levels for dynamic risk assessment and treatment monitoring
with an increase in troponins being associated with higher risk and
a decrease with lower risk (1).
The challenge for clinicians and guideline committees is to
decide how and when to use imperfect information to inform
clinical decisionsdwhile waiting for Godotdor more reliable ev-
idence from clinical trials comparing troponin-guided treatment
with usual care in populations at modest risk based on clinical
criteriadevidence that may or may not arrive.*Harvey D. White, DSc
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61:1906–13.Regarding the Effect
of Dabigatran Plasma
ConcentrationsThe paper by Reilly et al. (1) suggested that up to 20% of patients
using the 110 and 150 mg twice daily dosing will fall outside
of the optimal concentration range of 35 to 300 ng/ml. Recently
unsealed court documents reveal internal pharmaceutical corre-
spondence that suppressed important data regarding dabigatran
therapy for patients with atrial ﬁbrillation (2,3). Corporate e-mails
suggest that the range may be narrower (3). These data were
removed from the ﬁnal paper by Reilly et al. (1) to avoid losing the
marketing advantage of being a monitor-free anticoagulant (4,5).
Given that up to 20% of patients will fall out of range and be at
risk for irreversible major bleeding or inadequate anticoagulation,
one wonders how such an omission can be justiﬁed. Pharmaceutical
companies that prioritize proﬁt over patients damage their scientiﬁc
credibility. Perhaps pulling dabigatran from hospital formularies
will send a message that clinicians will not be complicit in un-
dermining the public trust.*Rama B. Rao, MD
*Division of Emergency Medicine
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Dabigatran Plasma
Concentrations
We would like to respond to Dr. Rao’s questions concerning our
paper (1). First, it is incorrect to state that any data on dabigatran and
plasma levels were suppressed. This information has been submitted
to all regulatory authorities as part of the original registration process
of dabigatran etexilate for reduction of stroke in patients with atrial
ﬁbrillation. These data have also been in the public domain since the
U.S. Food and Drug Administration (FDA) Advisory Committee
meeting in September 2010, before marketing approval (2).
Our paper, which investigated the exposure–response relation-
ship, documents plasma concentration as one factor affecting clinical
outcomes (1). Whether we could specify and defend a single
optimal concentration range for all patients was the subject of
extensive discussions among the coauthors. We ultimately came to
the conclusion that there is no single range that ﬁts all patients,
because individual patient demographics (e.g., age, renal function,
and prior stroke) are at least as important as the plasma concen-
trations in assessing beneﬁt–risk and confound the association
between drug levels and outcomes. Even with the high plasma
concentrations of dabigatran observed in patients with renal
dysfunction, the FDA has concluded there is a positive beneﬁt–
risk balance for patients (3). Further, RE-LY (Randomized Eval-
uation of Long-Term Anticoagulation Therapy) is the only trial of
a new oral anticoagulant that has published extensive data regarding
blood concentrations. It is likely that other anticoagulants will also
exhibit variability in blood concentrations.
Although it may appear attractive to monitor concentrations and
adjust dosing to improve outcomes, given the complex interactions
between plasma concentrations, demographics, and outcomes, we
cannot make recommendations on how to do this. In fact, without
routine testing in the RE-LY trial, dabigatran produces a clear net
beneﬁt over warfarin. The safety compared with warfarin has also
been conﬁrmed in post-marketing analyses by the FDA (4).*Paul A. Reilly, PhD
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